About Beyond Gender European Evidence
European evidence, country by country
This site records what European health authorities, courts and legislatures have decided about gender medicine and sex-based rights, one country at a time, with dates and sources.
Purpose
Europe is where the evidence base for youth gender medicine was built and where it was first re-examined. Finland's COHERE council, Sweden's Karolinska hospital and SBU agency, Norway's UKOM investigation board, the Dutch Amsterdam clinic and the French, German and Danish bodies that followed have each produced documents that are cited everywhere and read rarely. This site catalogues them.
How it is organised
Country dossiers each cover one national system: what it did, what it reviewed, what it changed and when. Cross-cutting dossiers cover the Dutch protocol, the systematic reviews and the European courts. The European timeline places every decision in order. The sources page collects the reviews, guidelines and judgments, with links to the originals in their own languages where available and to English translations where they exist.
Standards
Facts and dates first. Interpretation is marked as interpretation. National documents are preferred to press summaries. Corrections are welcome with a link to the original.
Point of view and publisher
The site is gender-critical. It regards the Nordic systematic reviews as the best evidence available and the Dutch protocol as an experiment whose own follow-up data did not support its export. It is published by Genspect, the international organisation founded in Ireland in 2021 with chapters across Europe, whose founder Stella O'Malley hosts the Beyond Gender podcast with Mia Hughes and Dr Bret Alderman.
Dossiers on the evidence base
The Dutch protocol: origins and follow-up data
Puberty blockers did not originate as a treatment for adolescent gender distress. Gonadotrophin-releasing hormone agonists, usually abbreviated to GnRH agonists or GnRHa, were already used in paediatric endocrinology to suppress unusually early puberty, and in other branches of medicine for hormone-sensitive conditions. The Dutch innovation was to apply these drugs to adolescents diagnosed with gender identity disorder, later termed gender dysphoria, as part of a staged pathway towards medical transition.
Detransition in Europe: studies and registries
“Detransition” is not a single measurable outcome. It can mean stopping puberty blockers or cross-sex hormones, reversing a legal sex marker, changing one’s name or presentation, seeking reconstructive or reversal treatment, or simply coming to regret an earlier medical decision. These are related but different events. A patient may cease hormones because of adverse effects, cost, fertility plans, health concerns, dissatisfaction, a changed identity, inadequate follow-up, or a temporary interruption; discontinuation is therefore not automatically proof of regret. Equally, recorded regret is no